Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunol Res. 2014 May;58(2-3):387-93. doi: 10.1007/s12026-014-8492-5.

Leukotrienes in pulmonary arterial hypertension.

Author information

1
VA Palo Alto Health Care System, Stanford University, Med111P, 3801 Miranda Ave., Palo Alto, CA, 94304, USA.

Abstract

Leukotrienes (LTs) are lipid mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism and are markers and mediators of pulmonary inflammation. Research over the past two decades has established that LTs modulate inflammation in pulmonary arterial hypertension (PAH). The purpose of this review was to summarize the current knowledge of LTs in the pathophysiology of PAH and to highlight a recent study that advances our understanding of how leukotriene B4 (LTB4) specifically contributes to pulmonary vascular remodeling. The results of these studies suggest that pharmacological inhibition of LT pathways, especially LTB4, has high potential for the treatment of PAH.

PMID:
24570092
PMCID:
PMC4031261
DOI:
10.1007/s12026-014-8492-5
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center